MYC and Familial prostate cancer: Thus, the concurrent inhibition of c-Myc and Abi or Doc may be a more effective strategy than the suppression of Abi or Doc alone in Prostatic cancer therapy and could especially be beneficial for patients who have become resistant to chemical-drug.